<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Franklin D Lowy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment failure for methicillin-resistant <em>Staphylococcus aureus</em> bacteremia with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> (or with teicoplanin, a glycopeptide structurally related to vancomycin used outside the United States) should prompt consideration of infection due to <em>S. aureus</em> with reduced susceptibility to vancomycin. </p><p>Reduced <em>S. aureus</em> susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> may occur via the following mechanisms (see <a class="local">'Overview of mechanisms'</a> below): </p><p class="bulletIndent1"><span class="glyph">●</span>Increased <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> minimum inhibitory concentration (MIC); known as "MIC creep" </p><p class="bulletIndent1"><span class="glyph">●</span>Cell wall alterations (as in the case of vancomycin-intermediate <em>S. aureus</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Plasmid-mediated horizontal gene transfer (as in the case of vancomycin-resistant <em>S. aureus</em>)</p><p></p><p>Issues related to the definitions, mechanism, epidemiology, and treatment of <em>S. aureus</em> bacteremia with reduced susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> will be reviewed here. Other issues related to <em>S. aureus</em> infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults"</a> and  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a> and  <a class="medical medical_review" href="/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H3433302925"><span class="h2">MIC breakpoints</span><span class="headingEndMark"> — </span>The Clinical and Laboratory Standards Institute (CLSI) and the US Food and Drug Administration have established the following <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> minimum inhibitory concentration (MIC) interpretive criteria for <em>S. aureus</em>. The definitions were modified in response to increasing reports of vancomycin treatment failure in infections due to strains with elevated MICs (2 mcg/mL) as well as to flag those isolates that are likely to be heteroresistant [<a href="#rid1">1-3</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> susceptible: ≤2 mcg/mL </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> intermediate: 4 to 8 mcg/mL </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> resistant: ≥16 mcg/mL </p><p></p><p></p><p>The acronyms for vancomycin-intermediate <em>S. aureus</em> (VISA), glycopeptide-intermediate <em>S. aureus</em> (GISA), and vancomycin-resistant <em>S. aureus</em> are derived from these criteria. VISA and GISA refer to the same susceptibility cutoff. The term VISA is more commonly used, although the term GISA may be more accurate since early reports indicated that most of these strains also had intermediate resistance to the glycopeptide teicoplanin.</p><p>The European Committee on Antimicrobial Susceptibility testing breakpoints differ from the CLSI breakpoints; ≤2 mcg/mL is considered susceptible and &gt;2 mcg/mL is considered resistant [<a href="#rid4">4</a>].</p><p>Reduced <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> susceptibility can rarely occur in <em>S. aureus</em> irrespective of background methicillin susceptibility and may result in increased tolerance to several classes of antibiotics [<a href="#rid5">5,6</a>]. </p><p class="headingAnchor" id="H67468403"><span class="h2">Heteroresistance</span><span class="headingEndMark"> — </span>Heteroresistant VISA (hVISA) refers to VISA strains in which subpopulations display variable rather than uniform susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid7">7,8</a>]. Heteroresistant strains of <em>S. aureus</em> contain subpopulations of bacteria with vancomycin MICs in the intermediate range, while the vancomycin MIC for the entire population of the strain remains within the susceptible range [<a href="#rid8">8</a>]. Like VISA strains, hVISA populations have accumulated mutations that help withstand vancomycin by means of an unusually thickened cell wall. (See <a class="local">'Overview of mechanisms'</a> below and  <a class="medical medical_review" href="/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Heteroresistance'</a>.)</p><p>The prototype heteroresistant strain was <em>S. aureus</em> Mu3, a clinical isolate recovered from a Japanese patient with staphylococcal pneumonia [<a href="#rid8">8</a>]. The reported frequency of heteroresistance is variable. Most studies describe a frequency of 0.5 to 1.5 percent, but frequencies as high as 20 percent have been reported in Japan [<a href="#rid2">2,8,9</a>].</p><p>It is uncertain whether heteroresistance is a cause of <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> treatment failure [<a href="#rid10">10-12</a>]. However, there are several reports of vancomycin failure and persistent infection due to hVISA [<a href="#rid13">13-15</a>]. In a review of 65 patients with endocarditis due to MRSA, 19 isolates (29 percent) exhibited the hVISA phenotype by population analysis profiling [<a href="#rid15">15,16</a>]. Patients with these isolates were more likely to have persistent bacteremia (68 versus 37 percent) and heart failure (47 versus 19 percent) [<a href="#rid15">15</a>]. Although screening for heteroresistance in clinical laboratories is not routinely performed, two studies noted the continued presence of these strains [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H1135065959"><span class="h1">OVERVIEW OF MECHANISMS</span><span class="headingEndMark"> — </span>Reduced <em>S. aureus</em> susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> can occur via the following mechanisms [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Increase in the minimum inhibitory concentration (MIC) of methicillin-resistant <em>S. aureus</em> (MRSA) isolates to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> (known as "MIC creep") – While these isolates have not necessarily reached the level of vancomycin resistance as vancomycin-intermediate <em>S. aureus</em> (VISA), they have been at the upper limits of the susceptible range. This has raised concern regarding the efficacy of vancomycin for treatment of clinical infections caused by these organisms [<a href="#rid3">3,19</a>]. (See <a class="local">'Borderline vancomycin susceptibility'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vancomycin-intermediate <em>S. aureus</em> (VISA) – The first clinical VISA isolate described in 1997, as well as subsequent isolates, were noted to have an unusually thickened cell wall containing excessive <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> target dipeptides (D-Ala-D-Ala) capable of "trapping" vancomycin, thereby reducing availability of the drug for cellular targets [<a href="#rid7">7,20-29</a>]. (See <a class="local">'Vancomycin-intermediate S. aureus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vancomycin-resistant <em>S. aureus</em> (VRSA) – The first clinical VRSA isolate, described in 2002, emerged via <em>vanA</em> gene plasmid-mediated transfer from enterococci with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> resistance to <em>S. aureus</em> via mobile genetic element Tn1546 (similar to mechanism of vancomycin-resistant enterococci emergence) [<a href="#rid30">30-34</a>]. (See <a class="local">'Vancomycin-resistant S. aureus'</a> below.)</p><p></p><p class="headingAnchor" id="H1979104799"><span class="h2">Borderline vancomycin susceptibility</span><span class="headingEndMark"> — </span>Issues related to borderline <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> susceptibility (when isolates approach the limit of the susceptible range [2 mcg/mL]) are discussed further separately. </p><p class="headingAnchor" id="H2850130699"><span class="h2">Vancomycin-intermediate S. aureus</span><span class="headingEndMark"> — </span>The genetic basis for cell wall alterations usually involves the stepwise acquisition of multiple mutations in genes that are two component regulatory systems [<a href="#rid35">35</a>]. Several studies have identified mutations in selected genes, including <em>vraR</em>, <em>graRS</em>, and <em>walRK</em>, that appear to contribute to cell wall synthesis and, as a result, to the development of resistance [<a href="#rid36">36-40</a>]. Downregulated genes also reduce expression of autolysins reducing cross-linking and autolysis [<a href="#rid35">35,41</a>]. The group II polymorphism at the accessory gene regulator locus is present in some VISA strains (as well as some MRSA strains) [<a href="#rid29">29,42</a>]. The increased metabolic demand caused by these thickened cell walls places these strains at a fitness disadvantage and may in part explain the limited instances of nosocomial spread of these strains in health care settings. In general, these strains appear to have attenuated virulence [<a href="#rid35">35</a>].</p><p>VISA strains often develop from MRSA strains that are exposed to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> for prolonged periods of time; this was suggested by the similarity between pulse-field gel electrophoresis patterns of the MRSA and subsequent VISA strains isolated from individual patients [<a href="#rid8">8,43-47</a>]. This course of events may have resulted from failure to eradicate the initial MRSA strain or subsequent reinfection with the same strain.</p><p>The colonial morphology of VISA strains may be different (eg, smaller or with different pigmentation) in part due to their slower growth rate [<a href="#rid31">31</a>]. (See <a class="local">'Diagnosis and laboratory testing'</a> below.)</p><p class="headingAnchor" id="H4069668302"><span class="h2">Vancomycin-resistant S. aureus</span><span class="headingEndMark"> — </span>A number of different plasmids have been identified that are capable of transferring the Tn1546 transposon, including those containing both enterococcal and staphylococcal plasmid deoxyribonucleic acid (DNA) [<a href="#rid48">48</a>]. VRSA resistance is due to the presence of the <em>van </em>gene cluster. Resistance is due to the synthesis of an alternative cell wall terminal peptide (D-ala-D-lac) rather than the normal terminal peptide (D-ala-D-ala). <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> is unable to bind to the first peptide. Expression of the <em>vanA</em> genes is only initiated by exposure to vancomycin so that there is limited effect on the fitness of the isolate (in contrast with the VISA strains). The instability of the plasmids in these strains may be one of the factors contributing to the failure of these strains to spread [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H1593593876"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Cases of <em>S. aureus</em> infections with reduced susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> continue to be described worldwide [<a href="#rid50">50,51</a>].</p><p class="headingAnchor" id="H1509092719"><span class="h2">VISA</span><span class="headingEndMark"> — </span>Several vancomycin-intermediate <em>S. aureus</em> (VISA) strains associated with clinical infection have been described [<a href="#rid7">7,10,43-47,52,53</a>]. The first reported case was observed in 1997 in Japan and occurred in a four-month-old with a surgical site infection. This original VISA strain was designated Mu50; its <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> minimum inhibitory concentration (MIC) was 8 mcg/mL [<a href="#rid7">7</a>]. The patient was successfully treated with <a class="drug drug_general" data-topicid="8676" href="/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> plus <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>. However, the first infection with VISA appears to have occurred in 1995 in France in a two-year-old with leukemia and central catheter–associated bacteremia; management was successful with surgical drainage and <a class="drug drug_general" data-topicid="9515" href="/d/drug information/9515.html" rel="external">quinupristin-dalfopristin</a> [<a href="#rid52">52</a>].</p><p>Subsequently, clinical infections with similar strains have been reported in the United States and around the world [<a href="#rid10">10,43-46,54-56</a>]. Features common to many of the United States cases included ongoing or recent dialysis, methicillin-resistant <em>S. aureus </em>(MRSA) bacteremia associated with central venous catheters or prosthetic graft material, and prolonged <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> exposure (6 to 18 weeks) in the three to six months preceding infection [<a href="#rid43">43,45-47,53</a>]. Contact investigation for two patients with VISA infection (including 177 contacts) yielded no VISA carriers [<a href="#rid43">43</a>]. There have also been a limited number of outbreaks associated with VISA strains, primarily in intensive care unit settings [<a href="#rid57">57,58</a>].</p><p>In general, the incidence of VISA is difficult to estimate given the rarity of infection and challenges related to laboratory detection. Surveillance data from the United States and Europe indicate that <em>S. aureus</em> isolates with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> MICs ≥4 mcg/mL represent less than 0.3 percent of MIC values [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H408891732"><span class="h2">VRSA</span><span class="headingEndMark"> — </span>There have been scattered reports of infection due to vancomycin-resistant <em>S. aureus</em> (VRSA) around the world.</p><p>Worldwide, 52 cases have been reported; in the United states, 14 cases have been reported [<a href="#rid48">48,59-67</a>]. The first United States case of VRSA was reported in 2002, isolated from a newly infected chronic foot ulcer in a patient in Michigan with diabetes, peripheral artery disease, and chronic renal failure on hemodialysis [<a href="#rid30">30</a>]. A strain of vancomycin-resistant <em>Enterococcus faecalis </em>(VRE) was also cultured from the ulcer, and DNA sequencing demonstrated that the <em>vanA</em> genes in the <em>Staphylococcus </em>and <em>Enterococcus </em>isolates were identical [<a href="#rid59">59</a>].</p><p>Additional cases were subsequently identified in Michigan as well as in Pennsylvania, New York, and Delaware. Most of the VRSA isolates were from skin and soft tissue sites, and most case patients were also colonized or infected with a VRE [<a href="#rid65">65</a>]. A comparative genomic analysis of the first 12 reported VRSA isolates concluded that resistance did not appear to be due to clonal dissemination of a single VRSA strain but rather represented separate events in which the plasmid containing the vancomycin-resistant transposon was acquired [<a href="#rid48">48</a>].</p><p>Sporadic cases have been reported elsewhere. The first case in Europe was reported in 2013 [<a href="#rid68">68</a>]. In 2014, a VRSA bloodstream infection caused by the epidemic, community-associated MRSA strain ST8 was reported in a young man in Brazil with diabetes who received several courses of antibiotics, including <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, for skin infections [<a href="#rid69">69</a>]. VRSA was subsequently isolated during teicoplanin therapy for a methicillin-resistant but vancomycin-susceptible <em>S. aureus</em> bacteremia. Genomic analysis demonstrated that the <em>vanA</em> sequence in the VRSA was identical to that in a VRE isolate subsequently recovered from a rectal swab.</p><p>Because cocolonization with MRSA and VRE is common, development of further VRSA strains remains a concern [<a href="#rid70">70,71</a>]. Although the majority of VRSA isolates reported to date have been from health care-associated MRSA strains, a few have been associated with community-acquired strains (as noted above for the bloodstream VRSA infection from Brazil), indicating the possibility of transferring plasmid-mediated <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> resistance to various MRSA strains. Secondary spread of these strains to health care workers appears to be limited [<a href="#rid66">66</a>].</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS AND LABORATORY TESTING</span></p><p class="headingAnchor" id="H909424772"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>In the setting of appropriate source control, repeated isolation of <em>S. aureus</em> from normally sterile sites despite seemingly appropriate therapy for longer than two to three days should prompt consideration of infection with a strain of <em>S. aureus</em> with reduced susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> that has emerged during therapy, even if the MIC of the original isolate was within the susceptible range [<a href="#rid2">2,72-79</a>]. Alternatively, persistent bacteremia may reflect an unrecognized abscess or metastatic infection (rather than reduced antibiotic susceptibility). </p><p>Persistent bacteremia may be defined as ≥2 days of bacteremia; the longer methicillin-resistant <em>S. aureus </em>(MRSA) bacteremia persists, the greater the risk of complications [<a href="#rid78">78,80,81</a>]. (See  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="headingAnchor" id="H2899925175"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Confirmatory MIC testing should be performed on <em>S. aureus</em> isolates for which the <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> MIC is ≥2 mcg/mL. Laboratory detection of <em>S. aureus </em>with reduced susceptibility to vancomycin may require special inquiry with the microbiology laboratory about susceptibility testing methods as discussed below [<a href="#rid82">82</a>].</p><p>An MIC susceptibility testing method (such as broth microdilution, agar dilution, or agar-gradient diffusion [E-test]) must be used for detection of <em>S. aureus</em> with reduced susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>; disk diffusion or automated methods are not sufficient [<a href="#rid83">83-86</a>]. A full 24-hour incubation period should be used with all methods. The use of matrix-assisted laser desorption/ionization time of flight mass spectrometry to distinguish vancomycin-susceptible <em>S. aureus</em> from vancomycin-intermediate <em>S. aureus</em> suggests that this newer technology may soon be able to rapidly detect these strains with reduced susceptibility to vancomycin [<a href="#rid87">87</a>].</p><p>The approach to <em>S. aureus</em> susceptibility testing should be tailored to the clinical scope of a particular laboratory [<a href="#rid56">56,88</a>]. Additional susceptibility testing is warranted in patients with repeated isolates of <em>S. aureus</em> from normally sterile sites despite seemingly appropriate therapy for longer than three to four days. Isolates should also be sent to the state public health laboratory or the United States Centers for Disease Control and Prevention for confirmatory evaluation when <em>S. aureus</em> with reduced susceptibility is suspected. (See <a class="local">'MIC breakpoints'</a> above.)</p><p>There is no validated laboratory test for routine detection of heteroresistant <em>S. aureus</em> populations; a number of methods have been described. The most accurate method consists of performing population analysis profiles [<a href="#rid16">16</a>]. As a result of this uncertainty, the Clinical and Laboratory Standards Institute lowered the intermediate <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> MIC breakpoint to 4 mcg/mL in order to flag isolates that are likely to be heteroresistant and/or clinically refractory to vancomycin therapy [<a href="#rid2">2</a>]. (See <a class="local">'Heteroresistance'</a> above and <a class="local">'MIC breakpoints'</a> above and  <a class="medical medical_review" href="/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Heteroresistance'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>General issues related to evaluation and management of <em>S. aureus</em> bacteremia and the duration of antibiotic therapy (which depends on the source of infection) are discussed separately. (See  <a class="medical medical_review" href="/d/html/2134.html" rel="external">"Clinical approach to Staphylococcus aureus bacteremia in adults"</a>.)</p><p>General issues related to treatment of methicillin-resistant <em>S. aureus </em>(MRSA) infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="headingAnchor" id="H504937060"><span class="h2">Borderline vancomycin susceptibility</span><span class="headingEndMark"> — </span>For patients with infection due to <em>S. aureus</em> isolates approaching the limit of the susceptible range (2 mcg/mL) who are not responsive to or are intolerant of <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a>, there are several potential alternative agents. The approach is discussed further separately. (See  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="headingAnchor" id="H3869691427"><span class="h2">Infection due to VISA or VRSA</span><span class="headingEndMark"> — </span>The optimal regimen for treatment of infection due to vancomycin-intermediate <em>S. aureus </em>(VISA) or vancomycin-resistant <em>S. aureus </em>(VRSA) infection is uncertain. Patients who respond (with clinical improvement and clearance of bacteremia) to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> may continue treatment with one of these agents. </p><p>For patients with VISA or VRSA bacteremia who do not respond clinically to treatment with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a>, our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with source control and proven absence of deep-seated infection, monotherapy is reasonable; possible regimens include <a class="drug drug_general" data-topicid="9535" href="/d/drug information/9535.html" rel="external">telavancin</a>, <a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">ceftaroline</a>, or <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> (if laboratory testing demonstrates susceptibility to the selected agent) [<a href="#rid89">89-93</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9535" href="/d/drug information/9535.html" rel="external">Telavancin</a> monotherapy may prove effective for treatment of MRSA bacteremia (thus far, available data largely reflect study of pneumonia); in a phase II trial of telavancin for treatment of bacteremia including 17 patients, cure rates were comparable for telavancin and standard therapy (88 versus 89 percent) [<a href="#rid91">91,94</a>]. <a class="drug drug_general" data-topicid="95502" href="/d/drug information/95502.html" rel="external">Dalbavancin</a> and <a class="drug drug_general" data-topicid="96543" href="/d/drug information/96543.html" rel="external">oritavancin</a> are long-acting lipoglycopeptides; data on these agents for the treatment of MRSA bacteremia is limited. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">Ceftaroline</a> monotherapy has been successfully used for invasive MRSA infections but not VISA or VRSA infections [<a href="#rid89">89,95,96</a>]. Ceftaroline has in vitro activity against VISA strains.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> is limited by toxicity [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">Daptomycin</a> monotherapy should not be used; this approach may increase the risk for emergence of resistance during therapy [<a href="#rid97">97</a>]. In addition, there is no role for use of <a class="drug drug_general" data-topicid="9515" href="/d/drug information/9515.html" rel="external">quinupristin-dalfopristin</a>, <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, or fluoroquinolones for treatment of <em>S. aureus</em> bacteremia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with concomitant deep-seated infection, combination therapy is warranted to minimize the likelihood of further emergence of resistance during therapy [<a href="#rid79">79,98,99</a>]. Based on the available data, we favor combination therapy with <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> (dosed at 8 to 10 mg/kg rather than 6 mg/kg intravenously daily) and <a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">ceftaroline</a>, if supported by susceptibility testing. This approach is based on data discussed separately. (See  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia", section on 'Combination therapy'</a>.) </p><p></p><p class="bulletIndent1">Other possible combination regimens include [<a href="#rid79">79</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">Daptomycin</a> plus a beta-lactam [<a href="#rid95">95,100-103</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> plus a hydrophilic beta-lactam [<a href="#rid104">104,105</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">Daptomycin</a> plus <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid106">106</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">Ceftaroline</a> plus <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid107">107</a>]</p><p></p><p class="headingAnchor" id="H14"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Special efforts to ensure compliance with contact precautions and handwashing should be instituted when patients are infected or colonized with <em>S. aureus</em> strains with reduced susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid57">57,108</a>]. Issues related to nasal decolonization and <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> bathing for prevention of <em>S. aureus </em>infection are discussed further separately. (See  <a class="medical medical_review" href="/d/html/4048.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Prevention and control"</a>.)</p><p>In addition, health care providers should be vigilant about removing temporary venous catheters when they are no longer needed and minimizing prolonged empiric antimicrobial therapy whenever possible [<a href="#rid74">74,109</a>].</p><p>Consultation with infectious disease specialists, hospital epidemiologists, the local health department, and the United States Centers for Disease Control and Prevention is appropriate for optimizing laboratory investigation, patient management, and infection control issues. (See  <a class="medical medical_review" href="/d/html/4042.html" rel="external">"Infection prevention: Precautions for preventing transmission of infection"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> − Failure of treatment for methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) bacteremia with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> should prompt consideration of infection due to <em>S. aureus</em> with reduced susceptibility to vancomycin, even if the minimum inhibitory concentration (MIC) is within the susceptible range. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> − Reduced <em>S. aureus</em> susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> may occur via increased vancomycin MIC (known as "MIC creep"), cell wall alterations (as in the case of vancomycin-intermediate <em>S. aureus</em> [VISA]), or plasmid-mediated gene transfer (as in the case of vancomycin-resistant <em>S. aureus</em> [VRSA]). (See <a class="local">'Overview of mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> − The Clinical and Laboratory Standards Institute definitions for <em>S. aureus</em> <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> minimal inhibitory concentrations are as follows (see <a class="local">'MIC breakpoints'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> susceptible: ≤2 mcg/mL</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> intermediate: 4 to 8 mcg/mL</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">Vancomycin</a> resistant: ≥16 mcg/mL</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical suspicion for reduced </strong><a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a><strong> susceptibility</strong> − In the setting of appropriate source control, repeated isolation of <em>S. aureus</em> from normally sterile sites despite seemingly appropriate therapy for longer than two to three days should prompt consideration of infection with a strain of <em>S. aureus</em> with reduced susceptibility to vancomycin that has emerged during therapy, even if the MIC of the original isolate was within the susceptible range. (See <a class="local">'Clinical suspicion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory testing</strong> − An MIC susceptibility testing method (such as broth microdilution, agar dilution, or agar-gradient diffusion) must be used for detection of <em>S. aureus</em> with reduced susceptibility to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>; disk diffusion or automated methods are not sufficient. (See <a class="local">'Laboratory testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> − The optimal regimen for treatment of infection due to vancomycin-intermediate <em>S. aureus</em> or vancomycin-resistant <em>S. aureus</em> infection is uncertain. (See <a class="local">'Infection due to VISA or VRSA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who respond (with clinical improvement and clearance of bacteremia) to <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> may continue treatment with one of these agents. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients do not respond clinically to treatment with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a>, our approach is as follows:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with source control and proven absence of deep-seated infection, we suggest monotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); possible regimens include <a class="drug drug_general" data-topicid="9535" href="/d/drug information/9535.html" rel="external">telavancin</a>, <a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">ceftaroline</a>, or <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with concomitant deep-seated infection, we suggest switching to combination therapy with <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> plus <a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">ceftaroline</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We continue combination therapy until bacteremia has cleared with resolution of fever and clinical improvement, then complete treatment with daptomycin monotherapy. </p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193.</a></li><li><a class="nounderline abstract_t">Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208.</a></li><li class="breakAll">Laboratory detection of Vancomycin-Intermediate/Resistant Staphylococcus aureus (VISA/VRSA). Center for Disease Control and Prevention. https://www.cdc.gov/hai/settings/lab/visa_vrsa_lab_detection.html (Accessed on January 3, 2024). https://www.cdc.gov/hai/settings/lab/visa_vrsa_lab_detection.html (Accessed on January 03, 2024).</li><li class="breakAll">The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. http://www.eucast.org.</li><li><a class="nounderline abstract_t">Pillai SK, Wennersten C, Venkataraman L, et al. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009; 49:1169.</a></li><li><a class="nounderline abstract_t">Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011; 204:340.</a></li><li><a class="nounderline abstract_t">Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40:135.</a></li><li><a class="nounderline abstract_t">Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670.</a></li><li><a class="nounderline abstract_t">Wong SS, Ho PL, Woo PC, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999; 29:760.</a></li><li><a class="nounderline abstract_t">Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001; 32:108.</a></li><li><a class="nounderline abstract_t">Røder BL, Wandall DA, Frimodt-Møller N, et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159:462.</a></li><li><a class="nounderline abstract_t">Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2010; 51 Suppl 2:S183.</a></li><li><a class="nounderline abstract_t">Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J Infect Dis 2009; 199:605.</a></li><li><a class="nounderline abstract_t">Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448.</a></li><li><a class="nounderline abstract_t">Bae IG, Federspiel JJ, Miró JM, et al. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009; 200:1355.</a></li><li><a class="nounderline abstract_t">Wootton M, Howe RA, Hillman R, et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47:399.</a></li><li><a class="nounderline abstract_t">Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268.</a></li><li><a class="nounderline abstract_t">McGuinness WA, Malachowa N, DeLeo FR. Vancomycin Resistance in Staphylococcus aureus . Yale J Biol Med 2017; 90:269.</a></li><li><a class="nounderline abstract_t">Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315.</a></li><li><a class="nounderline abstract_t">Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319:157.</a></li><li><a class="nounderline abstract_t">Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1:57.</a></li><li><a class="nounderline abstract_t">Cui L, Ma X, Sato K, et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 2003; 41:5.</a></li><li><a class="nounderline abstract_t">Sieradzki K, Tomasz A. Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus. J Bacteriol 1999; 181:7566.</a></li><li><a class="nounderline abstract_t">Cui L, Iwamoto A, Lian JQ, et al. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50:428.</a></li><li><a class="nounderline abstract_t">Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, et al. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J Antimicrob Chemother 1998; 42:199.</a></li><li><a class="nounderline abstract_t">Cui L, Murakami H, Kuwahara-Arai K, et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 2000; 44:2276.</a></li><li><a class="nounderline abstract_t">Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.</a></li><li><a class="nounderline abstract_t">Howden BP, Johnson PD, Ward PB, et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50:3039.</a></li><li><a class="nounderline abstract_t">Walsh TR, Howe RA. The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Annu Rev Microbiol 2002; 56:657.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565.</a></li><li><a class="nounderline abstract_t">Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23:99.</a></li><li><a class="nounderline abstract_t">Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992; 72:195.</a></li><li><a class="nounderline abstract_t">Clark NC, Weigel LM, Patel JB, Tenover FC. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005; 49:470.</a></li><li><a class="nounderline abstract_t">Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006; 42 Suppl 1:S25.</a></li><li><a class="nounderline abstract_t">Howden BP, Peleg AY, Stinear TP. The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect Genet Evol 2014; 21:575.</a></li><li><a class="nounderline abstract_t">Mwangi MM, Wu SW, Zhou Y, et al. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A 2007; 104:9451.</a></li><li><a class="nounderline abstract_t">Howden BP, Stinear TP, Allen DL, et al. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52:3755.</a></li><li><a class="nounderline abstract_t">Howden BP, McEvoy CR, Allen DL, et al. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog 2011; 7:e1002359.</a></li><li><a class="nounderline abstract_t">Shoji M, Cui L, Iizuka R, et al. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55:3870.</a></li><li><a class="nounderline abstract_t">Hafer C, Lin Y, Kornblum J, et al. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56:5845.</a></li><li><a class="nounderline abstract_t">Hu Q, Peng H, Rao X. Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus. Front Microbiol 2016; 7:1601.</a></li><li><a class="nounderline abstract_t">Sakoulas G, Eliopoulos GM, Moellering RC Jr, et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2002; 46:1492.</a></li><li><a class="nounderline abstract_t">Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999; 340:493.</a></li><li><a class="nounderline abstract_t">Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999; 5:147.</a></li><li><a class="nounderline abstract_t">Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340:517.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48:1165.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46:813.</a></li><li><a class="nounderline abstract_t">Kos VN, Desjardins CA, Griggs A, et al. Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with Methicillin-resistant S. aureus hospital-acquired infection in the United States. MBio 2012; 3.</a></li><li><a class="nounderline abstract_t">Foster TJ. Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. FEMS Microbiol Rev 2017; 41:430.</a></li><li><a class="nounderline abstract_t">Shariati A, Dadashi M, Moghadam MT, et al. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep 2020; 10:12689.</a></li><li><a class="nounderline abstract_t">Unni S, Siddiqui TJ, Bidaisee S. Reduced Susceptibility and Resistance to Vancomycin of Staphylococcus aureus: A Review of Global Incidence Patterns and Related Genetic Mechanisms. Cureus 2021; 13:e18925.</a></li><li><a class="nounderline abstract_t">Ploy MC, Grélaud C, Martin C, et al. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 1998; 351:1212.</a></li><li><a class="nounderline abstract_t">Park JW, Lee H, Kim JW, Kim B. Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea. Sci Rep 2019; 9:6236.</a></li><li><a class="nounderline abstract_t">Oliveira GA, Dell'Aquila AM, Masiero RL, et al. Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin. Infect Control Hosp Epidemiol 2001; 22:443.</a></li><li><a class="nounderline abstract_t">Kim MN, Pai CH, Woo JH, et al. Vancomycin-intermediate Staphylococcus aureus in Korea. J Clin Microbiol 2000; 38:3879.</a></li><li><a class="nounderline abstract_t">Hubert SK, Mohammed JM, Fridkin SK, et al. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 1999; 37:3590.</a></li><li><a class="nounderline abstract_t">de Lassence A, Hidri N, Timsit JF, et al. Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2006; 42:170.</a></li><li><a class="nounderline abstract_t">Sakai Y, Qin L, Miura M, et al. Successful infection control for a vancomycin-intermediate Staphylococcus aureus outbreak in an advanced emergency medical service centre. J Hosp Infect 2016; 92:385.</a></li><li><a class="nounderline abstract_t">Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.</a></li><li><a class="nounderline abstract_t">Tenover FC, Weigel LM, Appelbaum PC, et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 2004; 48:275.</a></li><li><a class="nounderline abstract_t">Whitener CJ, Park SY, Browne FA, et al. Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure. Clin Infect Dis 2004; 38:1049.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus--New York, 2004. MMWR Morb Mortal Wkly Rep 2004; 53:322.</a></li><li><a class="nounderline abstract_t">Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46:668.</a></li><li><a class="nounderline abstract_t">Limbago BM, Kallen AJ, Zhu W, et al. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J Clin Microbiol 2014; 52:998.</a></li><li><a class="nounderline abstract_t">Walters MS, Eggers P, Albrecht V, et al. Vancomycin-Resistant Staphylococcus aureus - Delaware, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:1056.</a></li><li><a class="nounderline abstract_t">Cong Y, Yang S, Rao X. Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. J Adv Res 2020; 21:169.</a></li><li><a class="nounderline abstract_t">Melo-Cristino J, Resina C, Manuel V, et al. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 2013; 382:205.</a></li><li><a class="nounderline abstract_t">Rossi F, Diaz L, Wollam A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med 2014; 370:1524.</a></li><li><a class="nounderline abstract_t">Furuno JP, Perencevich EN, Johnson JA, et al. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonization. Emerg Infect Dis 2005; 11:1539.</a></li><li><a class="nounderline abstract_t">Tenover FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin Infect Dis 2008; 46:675.</a></li><li><a class="nounderline abstract_t">Sakoulas G, Moise-Broder PA, Schentag J, et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398.</a></li><li><a class="nounderline abstract_t">Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002; 186:661.</a></li><li><a class="nounderline abstract_t">Song JH, Hiramatsu K, Suh JY, et al. Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 2004; 48:4926.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.</a></li><li><a class="nounderline abstract_t">Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43:e42.</a></li><li><a class="nounderline abstract_t">Kullar R, McKinnell JA, Sakoulas G. Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy. Clin Infect Dis 2014; 59:1455.</a></li><li><a class="nounderline abstract_t">Kullar R, Sakoulas G, Deresinski S, van Hal SJ. When sepsis persists: a review of MRSA bacteraemia salvage therapy. J Antimicrob Chemother 2016; 71:576.</a></li><li><a class="nounderline abstract_t">Minejima E, Mai N, Bui N, et al. Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis 2020; 70:566.</a></li><li><a class="nounderline abstract_t">Kuehl R, Morata L, Boeing C, et al. Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study. Lancet Infect Dis 2020; 20:1409.</a></li><li><a class="nounderline abstract_t">Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus. J Clin Microbiol 2009; 47:2013.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Laboratory capacity to detect antimicrobial resistance, 1998. MMWR Morb Mortal Wkly Rep 2000; 48:1167.</a></li><li><a class="nounderline abstract_t">Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36:1020.</a></li><li><a class="nounderline abstract_t">Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:327.</a></li><li><a class="nounderline abstract_t">Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39:539.</a></li><li><a class="nounderline abstract_t">Mather CA, Werth BJ, Sivagnanam S, et al. Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. J Clin Microbiol 2016; 54:883.</a></li><li class="breakAll">Centers for Disease Control and Prevention: Healthcare-associated Infections (HAI) http://www.cdc.gov/ncidod/dhqp/ar_visavrsa_algo.html (Accessed on August 20, 2009).</li><li><a class="nounderline abstract_t">Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents 2013; 42:450.</a></li><li><a class="nounderline abstract_t">Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. Clin Infect Dis 2009; 49:395.</a></li><li><a class="nounderline abstract_t">Corey GR, Rubinstein E, Stryjewski ME, et al. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus. Clin Infect Dis 2015; 60:787.</a></li><li><a class="nounderline abstract_t">Marcos LA, Camins BC. Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. Antimicrob Agents Chemother 2010; 54:5376.</a></li><li><a class="nounderline abstract_t">Balkhair A, Al Muharrmi Z, Darwish L, et al. Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid. Int J Infect Dis 2010; 14 Suppl 3:e227.</a></li><li><a class="nounderline abstract_t">Stryjewski ME, Lentnek A, O'Riordan W, et al. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study. BMC Infect Dis 2014; 14:289.</a></li><li><a class="nounderline abstract_t">Sakoulas G, Moise PA, Casapao AM, et al. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther 2014; 36:1317.</a></li><li><a class="nounderline abstract_t">Cosimi RA, Beik N, Kubiak DW, Johnson JA. Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review. Open Forum Infect Dis 2017; 4:ofx084.</a></li><li><a class="nounderline abstract_t">Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011; 66:1057.</a></li><li><a class="nounderline abstract_t">Holubar M, Meng L, Deresinski S. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches. Infect Dis Clin North Am 2016; 30:491.</a></li><li><a class="nounderline abstract_t">Nigo M, Diaz L, Carvajal LP, et al. Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158.</a></li><li><a class="nounderline abstract_t">Werth BJ, Sakoulas G, Rose WE, et al. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2013; 57:66.</a></li><li><a class="nounderline abstract_t">Barber KE, Werth BJ, Rybak MJ. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. J Antimicrob Chemother 2015; 70:505.</a></li><li><a class="nounderline abstract_t">Mehta S, Singh C, Plata KB, et al. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012; 56:6192.</a></li><li><a class="nounderline abstract_t">Barber KE, Rybak MJ, Sakoulas G. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. J Antimicrob Chemother 2015; 70:311.</a></li><li><a class="nounderline abstract_t">Davis JS, Sud A, O'Sullivan MV, et al. Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial. Clin Infect Dis 2016; 62:173.</a></li><li><a class="nounderline abstract_t">Claeys KC, Smith JR, Casapao AM, et al. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother 2015; 59:1969.</a></li><li><a class="nounderline abstract_t">Fabre V, Ferrada M, Buckel WR, et al. Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis. Open Forum Infect Dis 2014; 1:ofu046.</a></li><li><a class="nounderline abstract_t">Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998; 27:245.</a></li><li><a class="nounderline abstract_t">Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996; 17:356.</a></li></ol></div><div id="topicVersionRevision">Topic 3165 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18171250" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407040" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407040" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407040" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19769538" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21742831" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9249217" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9400512" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589883" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bacteremia caused by staphylococci with inducible vancomycin heteroresistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11118389" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10074954" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20731576" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serious infections caused by methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19199551" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14727222" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19811099" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11266410" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793988" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28656013" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vancomycin Resistance in Staphylococcus aureus .</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591266" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2968517" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2891921" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Vancomycin-resistant enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517819" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601215" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gradual alterations in cell wall structure and metabolism in vancomycin-resistant mutants of Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436693" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738837" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10952568" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709046" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940100" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142482" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12139181" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Staphylococcus aureus resistant to vancomycin--United States, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20065327" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1505742" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15616340" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16323116" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Vancomycin resistance in gram-positive cocci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23567819" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517606" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18644967" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22102812" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21628539" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948864" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27790199" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11959587" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10021469" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10081683" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10021472" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11266244" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9310213" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22617140" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparative genomics of vancomycin-resistant Staphylococcus aureus strains and their positions within the clade most commonly associated with Methicillin-resistant S. aureus hospital-acquired infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28419231" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antibiotic resistance in Staphylococcus aureus. Current status and future prospects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32728110" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34812309" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reduced Susceptibility and Resistance to Vancomycin of Staphylococcus aureus: A Review of Global Incidence Patterns and Related Genetic Mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9643727" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30996231" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11583214" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11015427" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Vancomycin-intermediate Staphylococcus aureus in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10523558" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355325" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26879881" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Successful infection control for a vancomycin-intermediate Staphylococcus aureus outbreak in an advanced emergency medical service centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672861" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12418544" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Vancomycin-resistant Staphylococcus aureus--Pennsylvania, 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693550" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095205" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15103297" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Vancomycin-resistant Staphylococcus aureus--New York, 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18257700" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24371243" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26402026" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Vancomycin-Resistant Staphylococcus aureus - Delaware, 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32071785" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23791472" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : First case of infection with vancomycin-resistant Staphylococcus aureus in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24738669" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Transferable vancomycin resistance in a community-associated MRSA lineage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16318693" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci co-colonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18257701" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184410" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195353" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561884" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17516396" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16886141" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25048852" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26565015" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : When sepsis persists: a review of MRSA bacteraemia salvage therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30949675" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32763194" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19420170" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11266245" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Laboratory capacity to detect antimicrobial resistance, 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9542929" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11294734" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356818" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Staphylococcus aureus with reduced susceptibility to vancomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26763961" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26763961" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23993067" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19569970" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25472944" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20876369" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20005763" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24884578" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25017183" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28702467" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393156" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27208769" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232309" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ceftaroline-Resistant, Daptomycin-Tolerant, and Heterogeneous Vancomycin-Intermediate Methicillin-Resistant Staphylococcus aureus Causing Infective Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690622" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070161" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246437" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22985884" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25125677" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26349552" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Combination of Vancomycin andβ-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605354" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25734118" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709870" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Vancomycin-resistant Staphylococcus aureus: infection control considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8805065" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
